- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
Rituxan shows promise as treatment for type-1 diabetes
A new study carried out by researchers at Indiana University School of Medicine in Indianapolis and published in the New England Journal of Medicine suggests that the monoclonal antibody rituximab may benefit people with type 1 diabetes by reducing their need for insulin.
Marketed as Rituxan by Roche and FDA approved in the treatment of non-Hodgkin's lymphoma as well as rheumatoid arthritis, rituximab actually helped patients produce some of their own insulin, although researchers urged caution in interpreting these results and stressed that they did not indicate a cure for the disease.
The phase II study, in which patients received four doses of Rituxan, is part of Roche's attempt to secure FDA approval for the drug as a treatment for type 1 diabetes, a disease which affects as many as two and a half million people in the US, according to the American Diabetes Association.
You can read more about this study at US News & World Report.